Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges: 2020-2025

Historic Amortization of Deferred Charges for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $800,000.

  • Xeris Biopharma Holdings' Amortization of Deferred Charges changed negligibly% to $800,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 20.18%. This contributed to the annual value of $3.0 million for FY2024, which is 36.37% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Amortization of Deferred Charges of $800,000 as of Q3 2025, which was down 0.00% from $800,000 recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Amortization of Deferred Charges ranged from a high of $844,000 in Q1 2025 and a low of $219,000 during Q1 2022.
  • Its 3-year average for Amortization of Deferred Charges is $700,364, with a median of $800,000 in 2025.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Amortization of Deferred Charges decreased by 12.75% in 2022, and later skyrocketed by 150.23% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Amortization of Deferred Charges (Quarterly) stood at $273,000 in 2021, then soared by 79.12% to $489,000 in 2022, then increased by 3.27% to $505,000 in 2023, then soared by 59.80% to $807,000 in 2024, then remained steady at $800,000 in 2025.
  • Its Amortization of Deferred Charges stands at $800,000 for Q3 2025, versus $800,000 for Q2 2025 and $844,000 for Q1 2025.